OrbiMed’s SelectQuote SLQT Stock Holding History

OrbiMed’s Portfolio SLQT Stock Details SLQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,255,000	Closed	-$31.8M	–	158
2020 Q2	$31.8M	Buy	+1,255,000	New	+$33.7M	0.45%	62

Other funds holding SLQT

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SFM

Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

OrbiMed's SLQT Position: Q3 2020 in Review

OrbiMed sold out of SelectQuote (SLQT) in Q3 2020, closing a stake of 1,255,000 shares — an estimated $31.8M sold.

OrbiMed first reported a position in SLQT in Q2 2020 and held it in 1 quarter. The position peaked at $31.8M in Q2 2020. 112 funds tracked by Wall St. Rank hold SLQT as of Q3 2020.

OrbiMed reported no remaining SelectQuote position as of Q3 2020 after selling out during the quarter.
OrbiMed sold 1,255,000 SelectQuote shares in Q3 2020, an estimated $31.8M.
OrbiMed first reported a position in SelectQuote in Q2 2020 and held it in 1 quarter.
OrbiMed's SelectQuote position peaked at $31.8M in Q2 2020.
112 funds tracked by Wall St. Rank held SelectQuote as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.